TBC
ANTIRETROVIRAL THERAPY
2011
2011
2007
1996
1995
1992
1987
1985
1983
1964
1930s
• Confirmation is published that a toddler has been "functionally cured" of HIV infection
• Confirmation is published that the first patient cured of HIV, Timothy Ray Brown, still has a negative HIV status, 4 years after treatment.
• Maraviroc, the first available CCR5 receptor antagonist, is approved by the FDA as an antiviral drug for the treatment of AIDS.
• Robert Gallo's discovery that some natural compounds known as chemokines can block HIV and halt the progression of AIDS is hailed by Science as one of that year's most important scientific breakthroughs.
•Saquinavir, a new type of protease inhibitor drug, becomes available to treat HIV. Highly active antiretroviral therapy (HAART) becomes possible.
•The first combination drug therapies for HIV are introduced. Such "cocktails" are more effective than AZT alone and slow down the development of drug resistance.
• AZT (zidovudine), the first antiretroviral drug, becomes available to treat HIV.
• March 2, FDA approves the first AIDS antibody screening tests for use on all donated blood and plasma intended for transfusion and product manufacture
.
•The PCR (polymerase chain reaction) technique is developed by Kary Mullis; it is widely used in AIDS research
•Jerome Horwitz of Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine synthesize AZT under a grant from the US National Institutes of Health (NIH). AZT was originally intended as an anticancer drug.
•Researchers estimate that sometime in the 1930s a form of simian immunodeficiency virus, SIV, jumped to humans in central Africa. The mutated virus became the first human immunodeficiency virus, HIV-1.
Prusoff did research in the 1950s that led to the first clinically used antiviral drug. But it is his contribution to the fight against AIDS for which he is best known. In the mid-1980s, Prusoff and his Yale colleague Tai-shun Lin showed that d4T, a failed cancer compound, was effective against HIV. Yale secured a patent for d4T and licensed it to Bristol-Myers Squibb. Marketed under the name Zerit, it became part of the first combination drug therapy for HIV. (9.1)
Prusoff did research in the 1950s that led to the first clinically used antiviral drug. But it is his contribution to the fight against AIDS for which he is best known. In the mid-1980s, Prusoff and his Yale colleague Tai-shun Lin showed that d4T, a failed cancer compound, was effective against HIV. Yale secured a patent for d4T and licensed it to Bristol-Myers Squibb. Marketed under the name Zerit, it became part of the first combination drug therapy for HIV. (9.1)
That’s the challenge a Senate subcommittee will explore on Tuesday at a hearing on how to narrow the gap. It’s mainly a vehicle one proposed solution — a proposal by Sen. Bernie Sanders (I-Vt.) that would award prize money rather than grant patent rights to manufacturers that develop new HIV drugs, allowing the medication to go straight to the generic market. (9.2)
That’s the challenge a Senate subcommittee will explore on Tuesday at a hearing on how to narrow the gap. It’s mainly a vehicle one proposed solution — a proposal by Sen. Bernie Sanders (I-Vt.) that would award prize money rather than grant patent rights to manufacturers that develop new HIV drugs, allowing the medication to go straight to the generic market. (9.2)
Stefan Sarafianos, PhD, assistant professor of microbiology and immunology at the MU School of Medicine, has identified a new mutation that allows HIV to elude treatment. His research recently appeared in the Journal of Biological Chemistry and Nature Structural & Molecular Biology. (9.3)
Stefan Sarafianos, PhD, assistant professor of microbiology and immunology at the MU School of Medicine, has identified a new mutation that allows HIV to elude treatment. His research recently appeared in the Journal of Biological Chemistry and Nature Structural & Molecular Biology. (9.3)
Site Designed by LC Shorter / Ms. Keller / Christian Brothers Highschool